Clinical Trial Update: Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma [Phase 3]

View source ↗

Summary

Phase 3 trial update reports efficacy and safety results for a combination of rAd-IFN with celecoxib and gemcitabine in malignant pleural mesothelioma; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Celecoxib (Celecoxib)
• Gemzar (gemcitabine)
• rAd-IFN (recombinant adenovirus interferon)

Snippet

Sponsor: Ferring Ventures Limited | Conditions: Malignant Pleural Mesothelioma | Phase 3 | Status: COMPLETED | Results posted: 2025-05-20